分子靶向治疗在晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的治疗中起着越来越重要的作用.肝细胞生长因子/c-MET(hepatocyte growth factor/c-MET, HGF/c-MET)信号通路在NSCLC的发生、发展及NSCLC患者对表皮生长因子受体抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI)的耐药方面都起着重要的作用,其已经成为NSCLC分子靶向治疗的又一热点.c-MET扩增或过表达被认为可能是继EGFR和间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因之后,NSCLC又一特征性的基因突变.HGF/c-MET抑制剂也在临床前的研究中取得良好的抗肿瘤效果.近期公布的一些Ⅱ期/Ⅲ期临床研究的数据显示,HGF/c-MET抑制剂可以使部分c-MET扩增或过表达的NSCLC患者生存获益.因此,本文就HGF/c-MET抑制剂治疗NSCLC的研究进展做一综述.%Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth fac-tor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another heat point in the molecular targeted therapy of NSCLC. c-MET ampliifcation or high expression was deemed to another signiifcant gene modiifcation beyond EGFR and ALK. In the preclinical studies, HGF/c-MET inhibitors have showed the promising anti-tumor effect. Recently, some phase Ⅱ/Ⅲ clinical trials have proved that these inhibitors could improve the survival of patients with NSCLC. Hence we performed this review to elaborate the research progress of c-MET inhibitor in the treatment of NSCLC.
展开▼
